Randomized Study of Obicetrapib in Combination With Ezetimibe
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This study will be a placebo-controlled, double-blind, randomized, phase 2 study in
participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of
obicetrapib and ezetimibe combination therapy.